2025-07-14 - Analysis Report
Okay, here's a report on TG Therapeutics Inc. (TGTX) based on the data you provided.

## TG Therapeutics Inc. (TGTX) Stock Analysis

**TG Therapeutics Inc. is a biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases.**

### 1. Performance vs. S&P 500 (VOO)

*   **TGTX Cumulative Return:** 64.71%
*   **VOO Cumulative Return:** 95.46%
*   **Absolute Divergence (Current):** -30.75%
*   **Relative Divergence:** 15.6% (This means the current divergence is positioned at the 15.6th percentile of its historical divergence range.)

**Analysis:** TGTX has underperformed the S&P 500 significantly over the period examined. The relative divergence indicates that the underperformance is near the lower end of its historical range, but still represents a considerable lag.

**Alpha/Beta Analysis:**

| Year       | CAGR     | MDD   | Alpha    | Beta  | Cap(B) |
| ---------- | -------- | ----- | -------- | ----- | ------ |
| 2015-2017  | -6.0%    | 56.5% | -35.0%   | -0.1  | 1.3    |
| 2016-2018  | -8.0%    | 58.6% | -26.0%   | 0.0   | 0.7    |
| 2017-2019  | 74.0%    | 58.6% | 44.0%    | 0.0   | 1.8    |
| 2018-2020  | 402.0%   | 58.6% | 382.0%   | -0.4  | 8.3    |
| 2019-2021  | 125.0%   | 63.5% | 76.0%    | -0.5  | 3.0    |
| 2020-2022  | -76.0%   | 70.4% | -78.0%   | -0.6  | 1.9    |
| 2021-2023  | -350.0%  | 70.4% | -368.0%  | -0.8  | 2.7    |
| 2022-2024  | 71.0%    | 73.1% | 45.0%    | -0.9  | 4.8    |
| 2023-2025  | 72.0%    | 73.1% | 24.0%    | 0.4   | 5.9    |

**Analysis:**

*   **CAGR:** The company's compounded annual growth rate (CAGR) has fluctuated significantly over the years, with periods of high growth and substantial declines.
*   **MDD:** The maximum drawdown (MDD) indicates the largest peak-to-trough decline during the period. High MDD values suggest significant risk and volatility.
*   **Alpha:** Alpha measures the stock's performance relative to the benchmark (S&P 500). Positive alpha indicates outperformance, while negative alpha indicates underperformance. The company has experienced both positive and negative alpha, with recent periods showing significant underperformance.
*   **Beta:** Beta measures the stock's volatility relative to the benchmark. A beta greater than 1 suggests higher volatility, while a beta less than 1 suggests lower volatility. The company's beta values have varied, indicating its sensitivity to market movements.
*   **Cap(B):** The capitalization (in billions of dollars) provides a measure of the company's size.

### 2. Recent Stock Price Movement

*   **Current Price:** $37.08
*   **Last Market Data:** Price: $37.40, Previous Close: $37.09, Change: +0.84%
*   **5-day Moving Average:** $36.85
*   **20-day Moving Average:** $36.50
*   **60-day Moving Average:** $37.12

**Analysis:** The current price is slightly above the 5-day and 20-day moving averages but below the 60-day moving average. The slight price increase in the last market indicates some positive momentum.

### 3. Technical Indicators

*   **Market Risk Indicator (MRI):** 0.3294 (Low Risk)
*   **RSI:** 55.25
*   **PPO:** 0.263
*   **Hybrid Signal:** cash_0%_Buy 90% of cash (5 shares - Safe - MRI:0.33) (Cash Ratio: 0% on 2025-07-10)
*   **Recent (20-day) Relative Divergence Change:** +0.5 (Short-term Increase)
*   **Expected Return:** -251.2% (Long-term, relative to S&P 500)

**Analysis:**

*   **MRI:** Indicates low market risk, suggesting a relatively stable environment.
*   **RSI:** The RSI of 55.25 suggests that the stock is neither overbought nor oversold.
*   **PPO:**  A positive PPO indicates that the shorter-term moving average is above the longer-term moving average, suggesting a potential uptrend.
*   **Hybrid Signal:** Suggests a "Buy" signal with high cash allocation, likely due to the low MRI and positive momentum.
*   **Divergence Change:** The increase in relative divergence indicates a short-term improvement in performance relative to the S&P 500.
*   **Expected Return:** The large negative expected return suggests significant long-term underperformance relative to the S&P 500, raising concerns about long-term investment prospects.
*  **Last-Market Change:** The positive price change of 0.84% from the previous close indicates a short-term positive trend, possibly influenced by recent news or market events.

### 4. Recent News & Significant Events

*   **July 11, 2025:** Major business developments, regulatory changes, or market events.
*   **July 12, 2025:** Analyst discussions of recent performance and outlook.
*   **July 14, 2025:** Notable stock volatility influenced by recent news, earnings reports, or executive actions.
*   **July 13, 2025:** Market experts highlight both risks and opportunities, advising investors to monitor news and announcements.

**Analysis:** The news suggests recent events are influencing the stock, causing volatility and attracting analyst attention.  Investors should closely monitor specific announcements for further insights.

### 5. Recent Earnings Analysis

| 날짜       | EPS   | 매출      |
| ---------- | ----- | --------- |
| 2025-05-09 | 0.03  | 0.12 B$   |
| 2024-11-07 | 0.03  | 0.08 B$   |
| 2024-08-09 | 0.05  | 0.07 B$   |
| 2024-05-06 | -0.07 | 0.06 B$   |
| 2025-05-09 | -0.07 | 0.06 B$   |

**Analysis:**

*   **EPS:** The company's earnings per share (EPS) has been fluctuating, with a mix of positive and negative values.
*   **Revenue:** The company's revenue has shown some growth, with the latest quarter reporting higher revenue compared to previous quarters.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter    | Revenue   | Profit Margin |
| ---------- | --------- | ------------- |
| 2025-03-31 | $0.12B    | 87.14%        |
| 2024-12-31 | $0.11B    | 85.77%        |
| 2024-09-30 | $0.08B    | 88.86%        |
| 2024-06-30 | $0.07B    | 88.70%        |
| 2024-03-31 | $0.06B    | 91.43%        |

**Capital and Profitability:**

| Quarter    | Equity    | ROE       |
| ---------- | --------- | --------- |
| 2025-03-31 | $0.24B    | 2.13%     |
| 2024-12-31 | $0.22B    | 10.49%    |
| 2024-09-30 | $0.19B    | 2.02%     |
| 2024-06-30 | $0.18B    | 3.87%     |
| 2024-03-31 | $0.16B    | -6.69%    |

**Analysis:**

*   **Revenue:** The company's revenue has been increasing over the past year.
*   **Profit Margin:** The profit margin has been consistently high, indicating efficient cost management.
*   **Equity:** The company's equity has been growing, suggesting a strengthening financial position.
*   **ROE:** The return on equity (ROE) has fluctuated, with periods of positive and negative values.

### 7. Overall Analysis

TG Therapeutics Inc. presents a mixed picture.  While it has shown some recent positive momentum in price and revenue, its long-term performance has significantly lagged the S&P 500. The company has a history of high volatility.  The low MRI suggests a relatively stable market environment, and the Hybrid Signal recommends a buy position. However, the extremely negative expected return raises serious concerns about long-term prospects. Recent news indicates significant events are affecting the stock, warranting close monitoring.  The high profit margins are a positive sign, but investors should carefully weigh the risks and potential rewards before investing.

**Recommendation:**  Due to the high volatility, underperformance relative to the S&P 500, and negative expected return, caution is advised.  Thorough due diligence, including a deep dive into the recent news and company announcements, is crucial before making any investment decisions. This stock may be suitable only for investors with a high-risk tolerance and a strong understanding of the biopharmaceutical industry.
